Metformin use before ICU admission in patients with severe lactic acidosis
Official title: Prognosis of Lactic Acidosis Upon Admission to Intensive Care According to the Existence of Prior Treatment With Metformin
Run by University Hospital, Strasbourg, France · NCT07300293 · Data updated 2026-11-12
This project will see if taking metformin before ICU admission changes survival for adults with type 2 diabetes who develop severe lactic acidosis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | November 6, 2024 |
| Main results expected | May 2026 |
| Study ends | May 2026 |
| Registry record updated | December 23, 2025 |
| Trial ID | NCT07300293 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) admitted to the CHU de Strasbourg ICU with documented lactic acidosis within 24 hours and a known pre-admission medication history including metformin use are ideal candidates for inclusion.
✕Probably not a fit
Patients without arterial blood gas measurements, with unknown prior medication history, or those who had limits placed on active therapy during the first 24 hours would not be expected to benefit from inclusion or the study's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will review medical records of adults admitted to the CHU de Strasbourg intensive care unit between January 1, 2014 and December 31, 2023 who had lactic acidosis (pH <7.35 and lactate ≥5 mmol/L) within 24 hours of admission. Patients will be grouped by whether they had been taking metformin in the days before ICU admission and compared for ICU survival and related outcomes. The analysis will exclude patients without arterial blood gas data, unknown prior treatment, or who had therapy limitations within the first 24 hours. Results aim to clarify the association between prior metformin exposure and prognosis in this high-risk ICU population.
Why it matters
Potential benefit: If a link is found, clinicians could better judge risks of prior metformin use in critically ill patients and improve early management decisions.
How similar studies have gone: Previous observational studies on metformin and lactic acidosis have shown mixed and sometimes conflicting results, so the question remains unsettled.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient (≥18 years) * Admitted to the intensive care unit of Hautepierre Hospital - Strasbourg University Hospital between January 1, 2014, and December 31, 2023 * Having experienced lactic acidosis (pH \<7.35 and lactate level ≥5 mmol/L) within the first 24 hours of hospitalization. Exclusion Criteria: * Patient without arterial blood gas measurements during the first 24 hours of admission * whose background treatment is unknown and could not be determined * for whom a limitation of active therapies was implemented before or during the first 24 hours of hospitalization
Where it's running
-
Service de Médecine Intensive - Réanimation - CHU de Strasbourg - France
Strasbourg, France Recruiting
Study contacts
- Study coordinator: Vincent CASTELAIN, MD, PhD
- Email: vincent.castelain@chru-strasbourg.fr
- Phone: 33 3.88.12.79.15
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Acute Blood Flow Restriction Walking in Type 2 Diabetes
This study tests whether adding blood flow restriction to treadmill walking affects immune cells in adults with type 2 diabetes.
-
Continuous Glucose Monitoring in Type 2 Diabetes Not on Insulin
This study tests whether using a continuous glucose monitoring system helps people with type 2 diabetes who aren’t using insulin to improve blood sugar control and quality of life.
-
Differentiating heart disease in autoimmune vs. type 2 diabetes
This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.
-
Lifestyle Metabotype Study B: Understanding Personalized Glucose Responses
This study tests how lifestyle, metabolism, and brain energy use relate to each person’s blood sugar response after meals, across people with and without prediabetes or type 2 diabetes.
-
Lifestyle Metabotype Study: How Daily Habits Shape Blood Sugar
This observational study tests whether personal lifestyle and biological factors can predict how a person’s blood sugar responds after meals.
-
Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes
This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.